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Abbreviations 
 
API: Active pharmaceutical ingredient  
AUC: Area under the curve 
BBB: Blood-brain barrier 
BCS: Biopharmaceutical classification system 
CGMP: Current good manufacturing practice 
Cmax: Maximum plasma concentration 
COPD: Chronic obstructive pulmonary disease 
D50: Volume median diameter  
D90: Volume diameter 90% undersize 
DCS: Developability classification system 
DPI: Dry powder inhaler 
FDA: United States Food and Drug Administration 
FPF: Fine particle fraction 
Frel: Relative bioavailability 
HPH: High-pressure homogenization 
HPMC: Hydroxylpropyl methylcellulose 
MIC: Minimum inhibitory concentration 
MMAD: Mass median aerodynamic diameter 
NCE: New chemical entity 
ODT: Orally disintegrating tablet 
PCL: Polycaprolactone 
PVA: Polyvinyl alcohol 
PVP: Polyvinylpyrrolidone 
SLS: Sodium lauryl sulphate 
tmax: Time to achieve maximum plasma concentration 
TPGS: D-α-tocopheryl polyethylene glycol succinate 
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Abstract 
Introduction: Nanosuspensions combine the advantages of nanotherapeutics (e.g. 
increased dissolution rate and saturation solubility) with ease of commercialisation. 
Transformation of nanosuspensions to solid oral and inhalable dosage forms 
minimises the physical instability associated with their liquid state, enhances patient 
compliance and enables targeted oral and pulmonary drug delivery.  
Areas covered: This review outlines solidification methods for nanosuspensions. It 
includes spray and freeze drying as the most widely used techniques. Fluidised-bed 
coating, granulation and pelletisation are also discussed as they yield nanocrystalline 
formulations with more straightforward downstream processing to tablets or capsules. 
Spray-freeze drying, aerosol flow reactor and printing of nanosuspensions are also 
presented as promising alternative solidification techniques. Results regarding the 
solid state, in vitro dissolution and/or aerosolisation efficiency of the nanocrystalline 
formulations are given and combined with available in vivo data. Focus is placed on 
the redispersibility of the solid nanocrystalline formulations, which is a 
prerequisite for their clinical application.  
Expert opinion:  A few solidified nanocrystalline products are already  on the 
market and many more are in development. Oral and inhalable nanoparticle 
formulations are expected to have great potential especially in the areas of 
personalised medicine and delivery of high drug doses (e.g. antibiotics) to the lungs, 
respectively.  
Keywords: dry powder for inhalation, matrix former, nanosuspension, 
redispersibility, solid oral dosage forms, solidification 
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Article highlights 
 Nanosuspensions are submicron dispersions of nanosized drug particles 
stabilised by surfactants, polymers or a mixture of both.  
 The main advantages of nanosuspensions are increased dissolution and 
saturation solubility, enhanced chemical stability and rapid commercialisation. 
 Transformation of nanosuspensions to the solid state ensures their long-term 
stability and increases patient compliance. 
 Various drying techniques, with some of them well established (e.g. spray 
drying) while others are less applied in pharmaceutical technology (e.g. 
aerosol flow reactor) have been used for the transformation of 
nanosuspensions to solid oral dosage forms and dry powders for inhalation.  
 Transformation of nanosuspensions to micron-sized nanoparticle agglomerates 
is a way to deliver higher doses to the lungs compared to the conventional 
adhesive mixtures approach using dry powder inhaler (DPI) formulations.  
 Formulation and solidification process parameters influence the 
redispersibility (reformation of nanoparticles upon rehydration), which is a 
prerequisite for their superior clinical performance. Addition of matrix 
formers is a common strategy in order to achieve redispersible solidified 
nanosuspensions. 
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1. Introduction 
 
Many of the new chemical entities (NCEs) arising from combinatorial screening 
(>40%) suffer from poor solubility in aqueous media and some of them 
simultaneously in organic solvents [1]. Benet [2] puts the figure of NCEs suffering 
from poor solubility at 90% while only 40% of marketed drugs are poorly soluble. 
Whilst the vast majority of NCEs fail due to lack of efficacy or safety, poor solubility 
is frequently encountered as one of the challenges in the development of NCEs, as in 
the most extreme cases it results in erratic absorption and low bioavailability. In the 
past, the pharmaceutical industry considered these compounds as highly risky 
development candidates [3]. However, nowadays mainly due to their prevalence, 
“industry consensus has shifted from an attitude of avoidance to one of acceptance as 
increasing research dedication is given to solving solubility challenges” [4]. One 
strategy for addressing solubility challenges is based on nanoparticles.  
 
Nanotechnologies are one of the most prevalent strategies not only for overcoming 
the problem of poor solubility and thus bioavailability, but also for targeted drug 
delivery. Therefore, the use of nanoparticles in drug delivery is gaining momentum 
and research on nanoparticulate formulations has expanded greatly in recent years. 
Different types of nanotherapeutics have been applied in drug delivery, such as 
nanocomplexes, nanoemulsions, polymeric micelles, liposomes, virosomes, polymeric 
nanoparticles and nanosuspensions [5]. 
 
Nanosuspensions, also called nanocrystals are submicron, colloidal dispersions of 
nanosized drug particles, stabilized by surfactants, polymers, or a mixture of both [6]. 
According to a stricter definition, a formulation should have a volume median 
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diameter (D50) below 1 μm and a volume diameter 90% undersize (D90) below 2.5 
μm to be classified as a nanosuspension [7,8]. The term nanocrystals, although 
implying the particles are in a crystalline state, which is true for the majority of 
reported cases, has been also extended to describe nanosized suspensions of partially 
crystalline or even amorphous drugs [9].  
 
For a nanosuspension to be stable, it must contain a third component known as 
stabiliser in addition to the solid particles and liquid, such as a surfactant and/ or 
polymer. Several theories have been proposed to explain how stabilisers function 
and contribute to the stability of nanosuspensions: i) the lowering of the 
interfacial tension, ii) the Derjaguin-Landau-Verwey-Overbeek (DLVO) theory 
and iii) the steric stabilisation theory [10]. Currently, the selection of their 
stabilisers is mainly based on trial and error. However, there is an increased interest in 
developing a rational approach to selecting the appropriate stabiliser based on the 
physicochemical properties of the drug under investigation [11,12]. 
 
Drug nanosuspensions have been suggested as a universal delivery approach for drugs 
that fall into classes II and IV of the Biopharmaceutics Classification system (BCS) 
[13,14]. However, according to the recently proposed Developability Classification 
System (DCS), the nanosuspensions are only beneficial as a formulation approach for 
class IIa drugs for which the dissolution rate is the rate-limiting step for absorption 
[15]. 
 
This review will focus on the conversion of liquid nanosuspensions to solid oral 
dosage forms and dry powders for inhalation. The reasons for the solidification of 
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nanosuspensions together with the various methods applied until now in order to 
achieve solidification, will be described in-depth. In vitro data on the dissolution 
and/or aerosolisation of solidified nanocrystalline formulations will be given together 
with available in vivo data. Finally, emphasis will be given to the factors affecting 
their redispersibility, which is required for their superior clinical performance.  
 
2. Advantages of nanosuspensions 
In general, the main advantages of nanosuspensions are: a) their increased dissolution 
rate and enhanced saturation solubility with consequent bioavailability improvement, 
b) their low toxicity1 and c) the improved chemical stability.  
 
The reduced particle size and high surface area per unit mass of the nanoparticles lead 
to a more rapid dissolution as described by the Nernst and Brunner equation [16,17]. 
Regarding the saturation solubility, which for drug particles in the micrometer range 
and above is a constant depending on temperature and dissolution medium, in the case 
of sub-micron particles it depends on their size and is reported as "apparent" 
saturation solubility [18]. The enhanced "apparent" saturation solubility of 
nanosuspensions has been attributed to the increased curvature of nanoparticles 
resulting in increased dissolution pressure and hence drug solubility as described by 
Ostwald-Freundlich [19]. Due to the increased dissolution rate and enhanced 
saturation solubility, nanosuspensions result in improved bioavailability [14,20].  
                                   
1 Recently, there is an increasing concern regarding nanotoxicology mainly due to the ability of 
nanoparticles to enter cells. The toxicity of nanoparticles is related to their cellular uptake and 
intracellular fate. According to the nanotoxicological classification system proposed by Müller et 
al. [21], nanocrystals are in the low/non-risk group. Their typical size (100 nm < d < 1000 nm) 
does not allow cell endocytosis and their biodegradable nature is associated with low danger of 
biopersistency. However, studies should be conducted on the interaction of nanocrystals with 
cells and their cellular uptake has to be considered when developing nanocrystalline-based 
products [21].   
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More specifically, regarding oral drug delivery, nanosuspensions have been used as a 
way to address the issue of low bioavailability with reduced food-effect compared to 
micronised drug [21,22]. Nanosuspensions also increase adhesiveness to the 
gastrointestinal mucosa leading to prolonged gastrointestinal residence time and thus 
enhanced uptake via the gastrointestinal tract [23]. Mucoadhesive nanosuspensions of 
the antiprotozoal drug buparvaquone containing chitosan were proposed as a drug 
delivery system against intestinal Cryptosporidium infections due to their increased 
gastrointestinal residence time and thus prolonged action [24]. 
 
The high drug loading of nanosuspensions compared to other formulation approaches 
(e.g. cyclodextrin formulations) is beneficial as it is associated with reduced toxicity 
due to the very small amounts of stabilisers/excipients used [25]. Formulating a drug 
as a nanosuspension has also been proposed as a method of improving chemical 
stability with respect to solution formulations. For example, quercetin 
nanosuspensions exhibited no significant change in drug content or color over 1 
month. In contrast, for the solution, a 28.3% reduction in drug content and 
discoloration was observed over the same period [26].  
 
Formulating drugs as nanosuspensions may change their pharmacokinetic profile and 
extend their therapeutic use, as in the case of melarsoprol, an organoarsenic 
compound. Melarsoprol as a nanosuspension was unable to cross the blood-brain 
barrier (BBB), but rather accumulated preferentially in the Mononuclear Phagocyte 
System, which is a family of cells comprising bone marrow progenitors. The high 
concentration of the drug in the bone marrow resulted in reduced arsenic-related 
encephalopathies, due to the inability of the formulation to cross the BBB, and opens 
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the way for the use of melarsoprol against refractory leukemias and other cancer 
diseases [27]. 
 
Apart from their superior clinical performance, nanosuspensions have attracted the 
interest of drug formulators as they can extend the life cycle of an active 
pharmaceutical ingredient (API) after patent expiration, as occurred for a fenofibrate 
nanosuspension launched by Abbott Laboratories [14]. Nanosuspensions are also 
suitable formulations for preclinical animal studies mainly due to their quantitative 
and easy oral administration [28]. Moreover, the techniques for the production of 
nanosuspensions (e.g. wet-bead milling) are easy to scale-up and can provide the 
amount required (10 ml up to a few liters) for toxicological and pharmacokinetic 
studies in animals, and for clinical trial material under current good 
manufacturing practices (CGMP) [25,29]. All these characteristics have resulted 
in the rapid commercialisation of nanosuspensions.    
 
The application of nanosuspensions in pulmonary drug delivery has been limited until 
recently. However, many of the advantages mentioned above can also be extended to 
this route of administration. Nanosuspensions have been proposed as a formulation 
approach to increase the dissolution rate and thus absorption of poorly water-soluble 
inhaled corticosteroids such as fluticasone propionate and budesonide [30].  Britland 
et al. [31] compared the bioavailability, emission characteristics and efficacy of a 
budesonide nanoparticulate formulation with those of a proprietary micronized 
suspension of the drug after delivery as a nebulized aerosol to a human airway 
epithelial culture cell line. For an equivalent dose, the budesonide nanosuspension 
achieved improved uptake, retention and efficacy in the culture cells. 
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Furthermore, there are two key advantages in using nanosuspensions instead of 
solution formulations for pulmonary delivery of drugs with poor aqueous solubility. 
Preparation of solutions requires the use of organic co-solvents while the need for co-
solvents is limited or even non-existent for the production of nanosuspensions. As a 
result, the danger of potential co-solvent related toxicity is reduced [32]. In 
nanosuspensions, the drug concentration is not limited by the solubility in the vehicle 
as is the case for solutions, allowing the delivery of higher doses in the lungs [32]. 
Exploiting this advantage, Rundfeldt et al. [33] prepared itraconazole 
nanosuspensions which achieved high and long lasting lung tissue concentrations well 
above the minimum inhibitory concentration (MIC) against Aspergillus species, when 
administered using standard mesh nebulizer technology. The high concentration 
achieved indicates the potential of itraconazole nanosuspensions as a treatment for 
allergic bronchopulmonary aspergillosis in patients with cystic fibrosis, administered 
only once daily. 
 
Finally, nanosuspensions can be used as formulations facilitating pulmonary drug 
discovery, as they are easy to dose with a syringe-type delivery device in preclinical 
animal studies [30].  The advantages of nanosuspensions for both oral and 
pulmonary drug delivery are summarised in Table 1.  
 
3. Production of nanosuspensions 
Methods for the production of nanosuspensions can be categorized as top-down and 
bottom-up methods, depending on the starting material. In top-down methods, such as 
wet-bead milling, high-pressure homogenization (HPH) and microfluidisation, the 
starting material comprises larger solid particles than the resulting nanoparticles and 
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mechanical processes are the fundamental mechanism causing particle size reduction. 
In bottom-up methods, particles are formed from the molecular level. Such methods 
are further subdivided into solvent evaporation (e.g. spray drying, electrospraying, 
cryogenic solvent evaporation, etc.) and antisolvent methods (e.g. liquid antisolvent, 
supercritical antisolvent, etc.) [34,35]. 
 
The main advantage of top-down over bottom-up methods is the production of 
nanosuspensions with high drug loading. Moreover, they do not involve harsh organic 
solvents since the solvent in which drug is dispersed, but not dissolved, is water for 
the majority of poorly water-soluble drugs, making the top-down methods eco-
friendly. This permits the formulation of many poorly soluble APIs, characterized as 
“brick dust”, suffering from poor solubility in a wide range of solvents. In general, 
because of the more streamlined process-flow and the solvent-free feature of top-
down methods, the majority of marketed and developmental nanosuspension-based 
pharmaceutical formulations have been produced by top-down methods (Table 2).  
 
In this review, the production methods of nanosuspensions will not be discussed in 
detail since several relevant reviews have been published [13,25,36]. Rather, focus 
will be given on the transformation of nanosuspensions to the solid form, which will 
in this text be referred to as "solid nanosuspensions". 
 
4. Solidification of nanosuspensions 
Liquid nanosuspensions are associated with physical instability issues including 
sedimentation, creaming, crystal growth (also known as Ostwald ripening), 
aggregation and solid state transformation. A detailed review of the physical and 
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chemical instability issues of drug nanoparticles has been provided by Wu et al.  [37]. 
These instability phenomena make it difficult to ensure that the particle size of the 
nanosuspensions will remain the same upon storage. Moreover, nanosuspensions, due 
to their liquid media, are prone to microbial growth upon storage whilst addition of 
antimicrobial preservatives has been reported to cause destabilisation of the 
nanosuspensions in some cases [38].  
 
On the other hand, solid dosage forms exhibit enhanced physical and chemical 
stability. In addition, there is a general preference of patients for solid oral forms over 
liquid forms, enhancing compliance [22,39]. Transformation of nanosuspensions to 
more convenient dosage forms (e.g. tablets, capsules, pellets, granules etc.) is required 
in order to expand the application of nanocrystalline-based formulations into late 
development and commercial stages [40]. 
 
Dry powder inhalers (DPIs) constitute one of the main types of inhalation devices for 
drug delivery to the lungs, and their market is estimated to reach over USD 31.5 
billion in 2018 [41]. The inherent stability of the dry powders, the ability to 
administer high doses, the absence of propellants and the easier use compared to 
pressurised metered-dose inhalers (pMDIs) as they are breath-actuated can explain the 
increasing popularity of DPIs (in patients ≥ 5 years old and with adequate inspiratory 
flow), especially in Europe and North America [42]. 
For pulmonary delivery the particles should have an aerodynamic diameter between 
1-5 μm so as to deposit in the lungs [43]. Therefore, delivery of individual 
nanoparticles to the lungs (with the exception of particles below 50 nm) appears to be 
problematic, as due to their submicron size, the probability of exhalation before 
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deposition is increased [44,45]. Moreover, nanoparticles tend to strongly aggregate 
upon aerosolisation under the normal airflow rates in passive DPIs and their cohesive 
nature makes their handling extremely difficult [46]. In order to overcome these 
limitations, the controlled agglomeration of nanoparticles to micron-sized clusters has 
been recently proposed as “an approach to harmonise the advantages of 
nanoparticles with the aerodynamics of small microparticles so as to achieve an 
improved bioavailability2 and aerosolisation behaviour of the drug” [47]. It is clear 
then, that solidifying nanosuspensions to respirable nanoparticle agglomerates of 1 - 5 
μm, is a prerequisite for administering nanoparticles effectively to the lungs using 
DPIs.  
 
From the above, it becomes clear that, in general, the reasons for solidification of 
nanosuspensions lies in the disadvantages of the liquid state and the advantages 
associated with solid dosage forms. The usual problem of solidifying the 
nanosuspensions is the difficulty of readily redispersing "solid nanosuspensions" to 
yield nanosuspensions upon hydration with aqueous media in vitro and in the 
biological fluids of the gastrointestinal tract or lungs.  
 
4.1. Methods of solidification 
Spray drying, spray-freeze drying, freeze drying, deposition as coatings, incorporation 
in granules and pellets, aerosol flow reactor and printing methodologies which have 
                                   
2 Regarding pulmonary drug delivery, drug absorption and local bioavailability depends upon the 
fraction of deposited drug that dissolves in the lungs. Mucociliary clearance and absorption are two 
competing mechanisms and this can lead to bioavailability reduction for drug particles with low 
dissolution velocity [48]. Nanoparticle-based formulations have been found to promote more rapid 
absorption following inhalation of poorly water-soluble drug that have dissolution-limited drug 
absorption (e.g. fluticasone propionate, beclomethasone dipropionate, budesonide, itraconazole, 
fentanyl)[49].  
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been applied for the solidification of nanosuspensions will be discussed in-depth in 
this review. 
 
Illustration of the various solidification techniques for the production of solid oral 
nanocrystalline dosage forms is given in Fig.1. Fig.2 summarises the solidification 
approaches for the preparation of inhalable micron-sized nanoparticle agglomerates 
with suitable aerodynamic properties for delivery to the lungs using DPIs. 
 
4.1.1 Spray drying  
Spray drying is a one-step process whereby a liquid feed is converted to a dried 
particulate form. The main principles behind spray drying are the atomization of the 
liquid feed into fine droplets by a nozzle and the evaporation of the solvent by means 
of a hot drying gas [50]. The characteristics of the produced particles (e.g. particle 
size distribution, shape, residual moisture content and density) can be controlled by 
adjusting the formulation and process parameters (e.g. feed rate, inlet temperature) 
during spray drying. This makes spray drying a fundamental particle engineering 
technique for the development of both oral and inhalable formulations. Moreover, it is 
a popular process, from an industrial perspective, as it is quicker and more cost-
effective compared to freeze drying. Some examples of spray drying applications in 
developing “solid nanosuspensions” for oral and pulmonary delivery will follow. 
 
Zuo et al. [51] prepared nanosuspensions of fenofibrate by wet-bead milling and then 
applied spray drying for their solidification with simultaneous incorporation of 
mannitol as a matrix former. They elucidated the effect of formulation and process 
parameters on the redispersibility of the produced powders and found that: a) a low 
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drug to mannitol ratio and b) an inlet temperature lower than the melting point of 
fenofibrate should be used in order to minimize irreversible aggregation. Finally, the 
spray-dried nanocrystalline formulation with the optimal redispersibility 
characteristics was compared with a commercial nanocrystalline formulation 
licensed by Pharma ULC in Canada. No significant differences were observed 
between the in vitro and in vivo performance of the two formulations (relative 
bioavailability, Frel: 89.6%).  
 
Freag et al. [52] prepared nanosuspensions of diosmin (350-550 nm) by acid-base 
neutralisation (bottom-up technique), which were spray dried in the presence or 
absence of mannitol. The intestinal permeation of the formulations was studied using 
the ex vivo technique of the non-everted sac. It was found that formulating diosmin as 
a nanosuspension remarkably improved the permeation of the drug while for the 
solidified nanosuspensions the permeability was dependent on the incorporation of 
mannitol. Nanosuspensions spray dried without mannitol exhibited a decreased 
permeation compared to the liquid nanosuspensions, which was attributed to 
incomplete dispersion within the sac. However, no decrease in permeation was 
observed for nanosuspensions solidified by spray drying together with mannitol, due 
to their enhanced redispersibility.  
Spray drying has a long tradition in pulmonary drug delivery and until now the 
majority of reported studies on the development of inhalable particles by this 
methodology have focused on spray drying of drug solutions. But, as spray drying is a 
rapid solidification procedure, the obtained particles (at least from solution feed) are 
usually amorphous with the characteristic example being that of salbutamol sulfate 
(albuterol sulfate) after spray drying from aqueous solution (Fig.3a) [53].  
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Amorphicity is regarded as a disadvantage for respirable particles as it is associated 
with the danger of recrystallisation upon storage, which may influence adversely the 
stability, dissolution, absorption and aerosolisation efficiency of the product [54]. 
Recently, a few studies on solidified nanosuspensions for the development of 
pulmonary formulations by applying spray drying have been reported. The observed 
important formulation factors and characteristics of the resulting respirable "solid 
nanosuspensions" are summarized below.  
 
Pilcer et al. [55] prepared carrier-free respirable agglomerated nanoparticle 
formulations of tobramycin with enhanced dispersion properties by combining high-
pressure homogenization with spray drying. This can be considered as an attractive 
formulation approach for treating lung infections as a high dose can be delivered to 
the site of infection reducing the side effects related to systemic antibiotic 
administration.  
 
Yamasaki et al. [56] prepared nanosuspensions of cyclosporine A by anti-solvent 
precipitation (bottom-up technique) using a multi-inlet vortex mixer. The 
nanosuspensions were spray dried after the addition of different amounts of mannitol 
(Fig.3b), resulting in respirable nanoparticle agglomerates with enhanced fine particle 
fraction (FPF> 50%). The drug in the nanoparticle agglomerates was found to be in 
the amorphous state and this was attributed to the method of nanosuspension 
production rather than to the spray-drying step. The authors also investigated the 
effect of cyclosporine A to mannitol mass ratio on the dissolution rate and on the 
aerosolisation performance of the solidified nanosuspensions and concluded that 
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mannitol, as a hydrophilic excipient, improved the dissolution rate of cyclosporine A, 
while not influencing the aerosolisation behaviour.  
 
Pomázi et al. [57] developed respirable nanoparticle agglomerates of meloxicam 
embedded in mannitol and other adjuvants (polymers and L-leucine), by applying 
high-pressure homogenisation followed by spray drying. The presence of the amino 
acid L-leucine was found to enhance the aerosolisation of the nanoparticle 
agglomerates due to decreased particle-to-particle adhesion [58]. The nanoparticle 
agglomerates of meloxicam were crystalline and exhibited enhanced in vitro 
aerosolisation (FPF > 53%, mass median aerodynamic diameter, MMAD < 3.52 μm) 
and dissolution performance. Similar results have been reported for nanoparticle 
agglomerates of itraconazole as a formulation approach for the treatment of 
pulmonary aspergillosis [59]. 
 
From the above it can be summarized that spray drying of nanosuspensions has great 
potential for the production of solid formulations with predefined solid state and 
enhanced dissolution and aerosolisation properties that can be either administered 
orally or via a DPI. Addition of matrix formers and careful selection of process 
parameters is essential for the production of solid nanosuspensions with enhanced 
redispersibility, a prerequisite for superior clinical performance. Therefore, spray 
drying of nanosuspensions can be used as a platform for the oral and pulmonary 
delivery of poorly water-soluble drugs.  
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4.1.2. Spray-freeze drying 
Spray-freeze drying is an alternative technique to spray drying, which has been used 
for the preparation of thermolabile inhalable particles, especially proteins [60]. In the 
spray-freeze drying process, the liquid feed is atomised by a nozzle and the atomised 
droplets are snap frozen in liquid N2. The iced droplets are then lyophilized in order to 
remove the frozen solvent (water) via sublimation and obtain a powdery product. In 
comparison to spray drying, the spray-freeze drying is a low-temperature 
solidification process that produces porous particles [61].  
 
Niwa and Danjo [62] applied spray-freeze drying for the preparation of phenytoin 
"solid nanosuspensions" with enhanced redispersibility. The nanosuspensions were 
prepared by wet-bead milling, with polyvinylpyrrolidone (PVP) and sodium lauryl 
sulphate (SLS) as dispersing agents, and were further solidified by spray-freeze 
drying and conventional spray drying. The spray-freeze dried particles comprised 
porous network structures in which drug nanocrystals were embedded (Fig.4a, b). 
Both their redispersibility and dissolution were improved compared to solid 
nanosuspensions produced by conventional spray drying. The superior properties of 
spray-freeze dried particles were attributed to the better penetration of water into the 
pores of the particles resulting in rapid reconstitution of nanosuspensions. 
Consequently, spray-freeze drying of drug nanosuspensions was suggested as a novel 
dissolution-enhancing technique for poorly water-soluble drugs.  
 
Few studies have been published regarding the spray-freeze drying of drug 
nanosuspensions to produce particles suitable for inhalation. Cheow et al. [63] 
prepared inhalable composite particles by spray-freeze drying suspensions of 
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levofloxacin-loaded polycaprolactone (PCL) nanoparticles, in order to avoid problems 
associated with the low melting point of PCL and the limitation of elevated 
temperature use, which is inevitable in spray drying. Prior to the spray-freeze drying, 
adjuvants such as mannitol or polyvinyl alcohol (PVA) were added to the 
nanosuspensions to act as cryoprotectants and also to ensure redispersibility of the 
particles produced. Porous inhalable particles with suitable flowability and 
redispersibility were produced when high adjuvant concentrations were used.  
 
From the above it appears that spray-freeze drying is an alternative method for the 
solidification of thermolabile drug nanosuspensions, where the use of spray drying is 
not appropriate. Moreover, regarding pulmonary drug delivery, spray-freeze drying 
allows the preparation of particles with large geometric diameters but still having 
suitable aerodynamic properties due to their high porosity/low particle density [63]. In 
this way the poor flowability problems usually associated with inhalable particles can 
be overcome.  
 
4.1.3. Freeze drying  
Freeze drying or lyophilisation is a classical process of removing water from high 
value products (e.g. antibiotics, enzymes, vaccines, etc.) without excessive damage, 
enhancing stability on storage and reconstitutable by adding water, or other suitable 
aqueous diluent, prior to use [64]. In freeze drying, the liquid solution or suspension is 
firstly frozen under atmospheric pressure and subsequently heated under vacuum to 
remove the ice crystals by sublimation. At the end of the process, a highly porous 
cake with low moisture is obtained. Freeze drying together with spray drying are the 
most commonly used techniques for the solidification of nanosuspensions due to their 
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easy application and scale up possibility and therefore industrial acceptability. Recent 
applications of freeze drying for the solidification of nanosuspensions to oral and 
pulmonary formulations have been the following. 
 
Fu et al. [65] prepared nanosuspensions of nimodipine by high-pressure 
homogenisation, which were then freeze dried so as to be transformed to the solid 
state. Freeze drying had no effect on the redispersibility of the nanocrystalline 
formulations compared to a commercial solid dispersion of nimodipine marketed by 
Bayer Healthcare Pharmaceuticals. However, when the in vitro and in vivo profiles 
were compared, while the freeze-dried nanocrystals exhibited lower dissolution than 
the solid dispersion under non-sink conditions, their bioavailability was 2.6-fold 
higher, providing a way to reduce the high administered dose of nimodipine 
associated with its extensive first pass metabolism. Moreover, according to the 
authors, focus should be placed on the permeability mechanisms of nanocrystals and 
especially on the role of enterocytes and M cells on their oral absorption, which may 
explain the unfavourable in vitro in vivo correlation.  
 
Lai et al. [66] prepared orally disintegrating tablets (ODTs) of piroxicam, using 
freeze-dried nanosuspensions as a way to enhance the drug’s dissolution rate and also 
minimise the unwanted effects associated with its oral administration (e.g. gastric 
irritation). The piroxicam nanosuspensions were prepared by high-pressure 
homogenisation and stabilised with Poloxamer 188. The type of excipient added to 
the nanosuspension prior to the freeze-drying step was found to influence the 
dissolution rate of the nanocrystalline formulations. Crosscarmellose and gelatine 
resulted in higher dissolution rate than a commercial piroxicam ODT product 
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marketed by Pfizer, while xanthan gum reduced dissolution rate which was 
attributed to the increased viscosity of the hydrated gum upon dissolution.  
 
For the formation of respirable nanoparticle agglomerates, El-Gendy et al. [47] 
employed freeze drying for the transformation of the nanosuspensions obtained by a 
controlled flocculation process (protocol under the name NanoClustersΤΜ, owned by 
Savara Pharmaceuticals). Budesonide nanoparticle agglomerates prepared by this 
protocol, exhibited enhanced dissolution rate compared to the raw drug and had 
MMAD 2.1 ± 1.8 μm (mean ± SD) on aerosolisation, appropriate for deep lung 
deposition of the particles. The NanoClustersΤΜ protocol has been applied for the 
preparation of nanoparticle agglomerates of various drugs, such as ciprofloxacin, 
paclitaxel, diatrizoic acid, nifedipine and fluticasone propionate (Fig. 4c) [47,67,68]. 
 
Although spray drying and freeze drying are the most widely used techniques for the 
solidification of nanosuspensions, the powders produced by these methods often 
suffer from poor flowability and high hygroscopicity. These limitations make their 
downstream processing into final dosage forms such as tablets and capsules 
challenging [69]. Therefore, other methodologies have been applied to transform 
nanosuspensions into solid oral dosage forms, e.g. deposition as coatings and 
incorporation in granulations and pellets.   
 
4.1.4. Deposition as coatings  
Layering of nanosuspensions onto the surface of multiparticulates (e.g. granules, 
pellets, sugar beads, non-pareils, etc.) using a fluidised-bed coater has been used as an 
alternative method for the solidification of nanosuspensions [69-71]. In this method, 
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sufficient amounts of excipients, such as d-α-tocopheryl polyethylene glycol succinate 
(TPGS) and hydroxypropyl methylcellulose (HPMC) are used, both to stabilise the 
nanosuspensions, and to act as coating agents, required to ensure nanoparticles adhere 
onto the multiparticulates [69]. 
 
Möschwitzer and Müller [71] produced mucoadhesive nanosuspensions of 
hydrocortisone acetate by high pressure homogenisation (HPH), which were 
stabilised by Poloxamer 407 and chitosan chloride. The nanosuspensions were 
layered onto the surface of sugar spheres using a fluidized-bed coater equipped with a 
Wurster insert and bottom sprayer. Using the same equipment, the layered cores were 
further coated with an enteric polymer containing methacrylic acid as functional 
group, to achieve a controlled-release profile. The authors highlighted the triple role 
of chitosan chloride in the formulations: stabiliser of the nanosuspension, binder in 
the layering process and mucoadhesive excipient. Formulations of layered 
nanosuspensions exhibited enhanced dissolution rates compared to those layered with 
a drug microsuspension.  
 
4.1.5. Incorporation in granules and pellets 
Figueroa and Bose [72] studied the incorporation of nanosuspensions in fluidized-bed 
granulates. Nanosuspensions of naproxen and a proprietary Novartis compound were 
prepared by wet-bead milling and were further sprayed onto a mannitol-based 
substrate using a fluidized-bed granulator. Spray mode was identified as a critical 
process parameter, with top spraying yielding granules with enhanced redispersibility 
and faster release rates than those produced by bottom spraying. In addition, in vivo 
studies regarding the proprietary Novartis compound in fasted beagle dogs revealed 
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no significant differences between the pharmacokinetic profiles of the parent 
nanosuspension and the granulated nanocrystalline formulation.    
 
Vergote et al. [73] prepared spray-dried nanosuspensions of ketoprofen with and 
without sodium lauryl sulphate (SLS) and applied melt pelletisation to incorporate 
them in a controlled-release formulation. The pellets incorporated the spray-dried 
nanosuspension of ketoprofen, drum-dried corn starch and microcrystalline wax. It 
was reported that incorporation of SLS during the preparation of the nanosuspension 
not only acted as a stabiliser but also helped to achieve complete drug release from 
the pellet matrix. The formulations containing nanocrystalline ketoprofen exhibited 
faster in vitro release than the wax-based pellets of microcrystalline drug and the 
commercial long-acting product. However, no significant differences in the area 
under the curve (AUC) values of the above formulations were observed, after oral 
administration to dogs [74]. The pellets containing nanocrystalline ketoprofen 
exhibited an in vitro burst release achieving a higher maximum plasma concentration 
(Cmax) and shorter time to achieve maximum concentration (tmax) than the commercial 
formulation. Tablets prepared by compressing the ketoprofen pellet formulations with 
placebo wax-based pellets containing disintegrant had an in vivo profile similar to the 
commercial product.  
 
It appears that fluidised bed coating or granulation as well as pelletisation can be 
attractive options for the incorporation of solid nanocrystalline formulations in 
multiparticulates. As a result, the benefits of nanoparticles and multiparticulates can 
be combined and the handling difficulties of the solid nanosuspensions could be 
resolved.  
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4.1.6. Use of the aerosol flow reactor 
The aerosol flow reactor, patented by Teicos Pharma, has been used for the 
solidification of nanosuspensions. It is a one-step continuous process involving the 
atomisation of a liquid feed into a carrier gas (usually N2) for drying. More 
specifically, the liquid feed is atomized by an ultrasonic air-jet nebulizer and the 
droplets produced, suspended in the carrier gas, are directed into a heated tubular 
laminar flow reactor with constant temperature where evaporation takes place [76]. 
Varying the temperature of the reactor tube was found to have an effect on the particle 
morphology. Specifically, increasing the reactor temperatures up to 160 o C increased 
the particle size due to formation of hollow nanoparticles. Above 160 o C, the trend 
was reversed and the morphology of the particle changed to smaller spherical 
particles with smooth surfaces, which was attributed to the collapse of the hollow 
structure of the nanoparticles [75]. 
 
Laaksonen et al. [76] prepared indomethacin nanosuspensions by wet-bead milling 
stabilised by Poloxamer 188. The nanosuspensions were diluted with an aqueous 
solution of mannitol and leucine and then solidified using the aerosol flow reactor. In 
this way, fast–dissolving composite microparticles of indomethacin nanocrystals 
embedded in a mannitol matrix and a leucine-rich coating layer were produced.  
 
Using the aerosol flow reactor technology, Raula et al. [77] prepared inhalable 
microparticles for the concomitant pulmonary administration of budesonide and 
salbutamol sulfate. Combination therapy has been found to be advantageous for 
the treatment of respiratory diseases by reducing the need for multiple therapies 
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and as a result it holds potential to improve patient adherence to medication and 
therapeutic outcomes. Especially for chronic obstructive pulmonary disease 
(COPD), combination therapy enables delivery of more than one drug to the 
same area of the lungs where they can exhibit synergistic action [78]. The method 
for the preparation of the inhalable microparticles was as stated above, with the 
difference that the budesonide nanosuspension was diluted with an aqueous solution 
of salbutamol sulfate, mannitol and leucine. The obtained microparticles exhibited 
improved dissolution properties, with budesonide nanocrystals dissolving in 20 min 
and at the same rate as salbutamol sulfate, ensuring that the drugs will have a 
synergistic effect at the site of deposition/action. The microparticles also had 
enhanced aerosolisation efficiency with FPF: ≈ 50%, due to the leucine coating, 
which reduced the adhesion between particles.  
 
4.1.7. Printing  
Printing technologies have been used as a deposition method of dissolved or dispersed 
APIs for the production of solid oral dosage forms and inhalable formulations [79,80]. 
The main advantages of printing technologies are the preparation of personalised 
medicines, precise dosing that is especially important for drugs with a narrow 
therapeutic index and the ability for administering a combination of drugs by printing 
multiple drug layers using barrier coatings [81]. Printing technologies applied up until 
now in pharmaceutical formulations involve inkjet printing, flexographic printing and 
3D printing.  
 
Pardeike et al. [81] prepared nanosuspensions of folic acid by high-pressure 
homogenisation and applied piezoelectric inkjet printing onto edible substrates (e.g. 
 27 
rice sheet) as the solidification technique. They stated that in this way the advantages 
of nanosuspensions as formulations for poorly water-soluble drugs were combined 
with the potential of preparing personalised medicines by printing.  
 
Flexographic printing has been characterised as a modern version of letterpress 
printing with the ability to print in almost any type of substrate. Its use for the printing 
of pharmaceutical formulations was first reported by Genina et al. [82]. Recently, 
Palo et al. [83] used flexographic printing for the conversion of nanosuspensions into 
solid dosage forms. Nanosuspensions of indomethacin and itraconazole, produced by 
wet-bead milling and stabilised by Poloxamer 407, were printed on edible substrates 
(e.g. rice paper). The authors reported that homogeneous distribution of nanocrystals 
on the substrates was achieved, without any evident aggregation. The dissolution rate 
of the nanocrystals incorporated in the printed formulations was found to be slightly 
lower than the liquid nanosuspension, but still much higher than the raw drug.  
 
All in all, printing of nanosuspensions is a rapid technique with great potential as it 
can be used as a screening tool and can also produce personalised dosage forms. 
 
5. Redispersibility of solidified nanosuspensions 
After the description of different methods that have been used for the solidification of 
nanosuspensions, it is important to highlight the need for production of redispersible 
solid nanosuspensions [8]. 
 
During the solidification processes (e.g. spray drying, freeze drying, etc.) the 
nanosuspensions are exposed to thermal or freezing stresses that may lead to phase 
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and composition changes of the formulations [84]. Moreover, as solidification 
progresses the solvent volume is reduced and this may lead to a decrease in the 
solubility of the stabiliser that may precipitate, destabilising the colloidal system 
[85,86]. Nanocrystals also start approaching each other as the volume of the liquid 
media is reduced and attractive forces (e.g. capillary and van der Waal’s) are 
developed among adjacent nanocrystals [87]. All these effects may cause irreversible 
aggregation of the nanocrystals and loss of the advantages of nanoformulations [88].  
 
A few studies have elucidated the factors involved in the irreversible aggregation of 
solid nanosuspensions. Van Eerdenbrugh et al. [86] studied the effect of spray drying 
and freeze drying of nanosuspensions on the dissolution properties of drugs with 
different physicochemical properties. They suggested that the tendency for 
irreversible aggregation of nanocrystals during solidification is mainly drug-
dependent. Solid nanosuspensions of drugs with high surface hydrophobicity (e.g. 
itraconazole) exhibited decreased dissolution compared to the liquid nanosuspension. 
The same trend occurred between log P of the drugs and dissolution of the solid 
nanosuspensions. The authors concluded that during solidification, drugs with higher 
surface hydrophobicity and/or log P resulted in aggregates that were harder to 
disintegrate than drugs with higher hydrophilicity.  
 
Yue et al. [8] studied the effect of various stabilisers on the redispersibility of solid 
suspensions of baicalin. Compared to other stabilisers, tocopherol polyethylene glycol 
succinate (TPGS) was more effective in protecting baicalin nanosuspensions from 
detrimental effects during solidification. This was explained by the high affinity of 
TPGS for the drug crystals and the strong surface adsorption. As a result, the polymer 
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chain of TPGS has the ability to counter effectively the solidification-related stresses 
faced by the nanocrystals. The inferior performance of other stabilisers (e.g. HPMC, 
methylcellulose, polyvinylpyrrolidone K30, Tween 80, etc.) was attributed to polymer 
chain entanglement during solidification. In this study, the solidification methods 
used included spray drying, freeze drying and vacuum drying. By varying the process 
parameters, it was found that drying the nanosuspensions at higher temperatures 
negatively impacted their redispersibility. Regarding freeze drying, increasing the 
freezing rate was found to enhance the redispersibility of the formulations [8]. 
Contradictory results have been reported in other studies with respect to whether a 
fast or slow freezing rate prevents irreversible aggregation of nanocrystals [85]. 
However, it is evident that in order to achieve successful solidification, process 
parameters should be selected carefully and working within well-defined processing 
windows is necessary [89]. 
 
The most common way to enhance the redispersibility of solid nanocrystals is the 
incorporation of bulking agents/matrix formers as a part of the formulation before the 
solidification step. The matrix former should immediately dissolve upon redispersion 
releasing the nanocrystals into the dispersion medium (Fig.4). Water-soluble sugar-
based compounds such as mannitol, sucrose and lactose have been the most 
commonly used matrix formers. However, the list of excipients investigated as matrix 
formers is continuously expanding, with microcrystalline cellulose and even clay 
reported to enhance the redispersibility of solid nanosuspensions [89,90]. A detailed 
study on the effect of sugars as bulking agents in order to prevent nanocrystal 
aggregation during spray and freeze drying has been provided by Kumar et al. [91]. 
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6. Conclusions 
Nanosuspensions are a useful formulation approach for an ever-increasing number of 
poorly water-soluble drugs in the industrial pipeline. Transformation of 
nanosuspensions from the liquid form to the solid state can help to ensure their long-
term stability and potentially increase patient compliance. A range of drying 
techniques, some well-established, others with only few years of application in the 
area of pharmaceutical technology, have been used for transformation of 
nanosuspensions to solid oral dosage forms and dry powders for inhalation. The 
“solid nanosuspensions” are recognised as advanced formulations compared to 
traditional systems. The number of nanocrystalline-based products already 
commercially available, the increasing number of scientific publications and patents 
in this area from several research groups, indicate that both the pharmaceutical 
industry and academia have embraced this flexible formulation approach, which is 
estimated to advance even more over the coming years [92,93].  
 
7. Expert opinion 
Nanosuspensions combine the advantages of increased dissolution rate and saturation 
solubility, low toxicity and enhanced chemical stability. In this way, nanocrystals are 
one of the most industrially feasible aspects of nanotechnology, with some 
nanocrystalline-based products already on the market and others in development. 
Transformation of nanosuspensions from the liquid to the solid state can help to 
ensure their long-term stability, increase patient compliance and also open the way for 
the pulmonary administration of nanoparticles using DPIs.  
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Regarding the oral administration of “solid nanosuspensions”, spray and freeze drying 
are the most commonly used techniques; the powders produced being blended with 
other excipients and either filled into capsules or compacted to tablets. Fluidised-bed 
coating or granulation as well as pelletisation are alternative solidification techniques 
having the advantage of a more straightforward downstream processing to a final 
product (multiparticulates in capsules or tablets). Printing of nanosuspensions is a 
rapid technique with great potential as it can be used as a screening tool but can also 
produce personalised dosage forms. 
 
Conversion of nanosuspensions to micron-sized nanoparticle assemblies with suitable 
aerodynamic properties can be used as a platform for the delivery of poorly water-
soluble drugs to the lungs using DPIs. This platform, after suitable modifications, can 
also benefit the aerosolisation of water-soluble drugs [94,95]. Spray drying and the 
aerosol flow reactor have been successfully applied for the production of inhalable 
nanoparticle agglomerates with enhanced dissolution and aerosolisation efficiency. 
Spray-freeze drying of nanosuspensions produced larger lower density nanoparticle 
agglomerates, which were still suitable for pulmonary drug delivery and also 
exhibited better flowability. As spray drying is a well-established technique in particle 
engineering for pulmonary drug delivery and also popular from an industrial 
perspective, it is likely to be the technique of choice for the scaling up and 
commercialisation of the concept of respirable nanoparticle agglomerates.  
 
One of the current limitations is the empirical nature of the stabiliser selection for the 
production of nanosuspensions. At present there is no systematic approach to guide 
the choice of stabiliser with respect to the active ingredient. Focus should be given to 
approaches such as molecular modelling and scanning probe microscopy that can 
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provide valuable insight into the way the stabiliser adsorbs to the surface of the 
crystal particles [96,97]. In this way, these two techniques may be able to prioritise 
and narrow down the number of stabilisers that need to be screened. Moreover, 
potential within the areas of nanosuspension preparation and solidification can be 
accelerated with the implementation of the concept of quality by design [98]. In this 
way, the knowledge of the interplay between formulation, process and quality 
attributes will facilitate rational design of nanocrystalline-based formulations.  
 
Regarding pulmonary drug delivery, one of the distinct advantages of inhalable 
nanoparticle agglomerates is their enhanced aerosolisation performance even without 
the addition of carrier particles (e.g. lactose). In this way, high drug payloads can be 
administered to the lungs, which are difficult with the traditional approach of adhesive 
mixtures of carrier particles and micronised drug. This approach can revolutionise 
the administration of antibiotics to patients with chronic respiratory conditions 
(e.g. cystic fibrosis), as it enables local delivery of higher drug concentration at 
the lung tissue while concentrations elsewhere are kept at a minimum. In this 
way, maximum therapeutic effect can be achieved by administering lower 
inhaled doses compared to those required for systemic administration, and as a 
result side effects can be minimised.  
 
Finally, future studies should generate more in vivo data, especially concerning the 
pulmonary drug delivery of nanoparticle agglomerates, so as to ensure that the 
beneficial in vitro properties of this formulation approach are translated in superior 
clinical performance and pave the way for new therapies worldwide.  
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Table 1 Advantages of nanosuspensions 
General advantages 
 Dissolution rate 
 Saturation solubility 
 Bioavailability 
 Chemical stability 
 Drug loading 
 Excipient-related toxicity 
Route of administration                      Advantages 
Oral  Food effect 
 Gastrointestinal residence time 
 Quantitative & easy administration to preclinical animal studies 
 Extension of the life cycle of off- patent drugs 
Pulmonary  Delivery of high drug concentrations to the lungs 
 No need for co-solvents  
 Ease of dosing using syringe in animals (intratracheal instillation) 
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Table 2 Commercially available and developmental nanocrystalline formulations [13,25] 
Trade name, 
Company 
Active substance Indication Particle size reduction 
technology 
Status 
(FDA 
approval) 
Route Dosage form Solidification 
technique 
Rapamune®, Wyeth  Sirolimus Immunosuppresant Elan NanoCrystals® Marketed 
(2000) 
Oral Suspension 
Tablet 
          _- 
Tablet coating 
Emend®,  
Merck  
Aprepitant  Antiemetic Elan NanoCrystals® Marketed 
(2003) 
Oral Hard gelatin capsule 
containing pellets 
Bead coating 
TriCor®,  
Abbott 
Fenofibrate Antihyperlipidemic Elan NanoCrystals® Marketed 
(2004) 
Oral Tablet Granulation 
Triglide®,  
First Horizon 
Pharmaceuticals 
Fenofibrate Antihyperlipidemic SkyePharma IDD®-P  Marketed 
(2005) 
Oral  Tablet Spray drying 
Megace ES®,  
PAR Pharmaceutical 
Megestrol acetate Appetite stimulant Elan NanoCrystals® Marketed 
(2005) 
Oral Suspension           - 
Invega® SustennaTM,  
Jonshon & Johnson 
Paliperidone 
palmitate 
Antipsychotic Elan NanoCrystals® Marketed 
(2009)  
Intramuscular  Suspension in prefilled 
syringe 
          - 
Semapimod, Cytokine 
PharmaSciences 
Guanylhydrazone TNF-a inhibitor Self developed Phase II Oral         -         - 
TheraluxTM, 
Celmed Biosciences 
Thymectacin Anticancer Elan NanoCrystals® Phase II Intravenous        -         - 
NPI 32101,  
Nucryst 
Silver                                                 Antimicrobial                                        Magnetron sputtering Phase II                                                                               Topical                                                                                                                                          - -
Zolip®,  
Solvay Pharmaceuticals 
(now Abbott) 
Fenofibrate/ 
Simvastatin 
Antihyperlipidemic Elan NanoCrystals® Phase III Oral Tablet       n/a 
Budesonide, Sheffield 
Pharmaceuticals                   
Budesonide Antiasthmatic                                                                                                                                                                                                                                 Elan NanoCrystals® Phase III Pulmonary Suspension administered 
via nebulizer 
-
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Figures 
 
Figure 1. Schematic representation of the various solidification techniques for the 
production of solid oral nanocrystalline dosage forms. 
 
Figure 2. Schematic representation of the various solidification approaches for the 
preparation of inhalable micron-sized nanoparticle agglomerates. 
 
Figure 3. Scanning electron microscopy images of (a) spray dried salbutamol sulfate 
from 10% w/v aqueous solution, taken from [53] with permission and (b) spray dried 
nanosuspension of cyclosporine A containing mannitol (1:0.5 mass ratio), taken from 
[56] with permission. 
 
Figure 4.  Scanning electron microscopy images of (a,b) spray freeze-dried 
nanosuspensions of phenytoin and PVP (1:1 mass ratio) at different magnifications, 
taken from [62] with permission and (b) freeze dried nanoparticle agglomerates of 
nifedipine, taken from [68] with permission.  
Figure 5. Schematic representation of the matrix former influence on redispersibility 
of solidified nanosuspensions upon their rehydration. 
 
 
 
 
Figure 1. Schematic representation of the various solidification techniques for the 
production of solid oral nanocrystalline dosage forms. 
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Figure 2. Schematic representation of the various solidification approaches for the 
preparation of inhalable micron-sized nanoparticle agglomerates. 
 
 
 
 
Figure 3. Scanning electron microscopy images of (a) spray dried salbutamol sulfate 
from 10% w/v aqueous solution, taken from [53] with permission and (b) spray dried 
nanosuspension of cyclosporine A containing mannitol (1:0.5 mass ratio), taken from 
[56] with permission.  
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Figure 4. Scanning electron microscopy images of (a,b) spray freeze-dried 
nanosuspensions of phenytoin and PVP (1:1 mass ratio) at different magnifications, 
taken from [62] with permission and (b) freeze dried nanoparticle agglomerates of 
nifedipine, taken from [68] with permission.  
 
 
 
 
Figure 5. Schematic representation of the matrix former influence on redispersibility 
of solidified nanosuspensions upon their rehydration. 
 
 
